Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 8—August 2002

Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons

Arturo CasadevallComments to Author 
Author affiliation: *Albert Einstein College of Medicine, Bronx, New York, USA

Main Article


Therapeutic and prophylactic strategies to combat biological warfare agent.

Strategy Advantages Disadvantages
Antimicrobial chemotherapy Relatively cheap
Oral administration
Self-administration Potential for superinfection
Selection for bystander resistance
Continuous use needed for efficacy
Drug-dependent side effects
Organisms can be engineered for resistance
Long development time to licensure
Vaccines Long-lasting protection Low public acceptance to theoretical threat?
Immune response requires time
Uncertain efficacy in compromised hosts
Potential for deleterious immunologic sequelae
Long development time to licensure
Passive antibody Immediate protection, lasting weeks or months
Low toxicity for human antibodies
Shorter development time to licensure?
Potential for self-administration Will probably require cold chain
Need for systemic administration
Agents can be engineered for resistance
Potential for infusion related reactions

Main Article

Page created: April 19, 2012
Page updated: April 19, 2012
Page reviewed: April 19, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.